Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials.

Author: GengQiang, LiXuan, SunQingjiao, WangZhengzhong

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This study evaluated the efficacy and safety of three PCSK9 inhibitors – alirocumab, evolocumab, and bococizumab – in patients with atherosclerotic cardiovascular disease (ASCVD).
Paper Details　
Original Abstract of the Article :
Safety concerns about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors make physicians reluctant to prescribe agents for patients. The present aim was to assess the efficacy and safety of alirocumab, evolocumab and bococizumab in patients with atherosclerotic cardiovascular disease (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273234/

データ提供：米国国立医学図書館（NLM）

PCSK9 Inhibition: A New Oasis for Cardiovascular Health

The field of [cardiovascular medicine] is constantly searching for new and effective treatments to manage [atherosclerotic cardiovascular disease (ASCVD)]. This study, utilizing a [meta-analysis] approach, examines the [efficacy and safety] of [proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors] in patients with ASCVD. The authors aim to provide a comprehensive overview of the available evidence and address any concerns regarding the use of these agents.

PCSK9 Inhibitors: A Promising Oasis

The meta-analysis, encompassing a vast dataset from multiple trials, reveals the [efficacy of PCSK9 inhibitors] in lowering [low-density lipoprotein cholesterol (LDL-C)] levels and reducing the risk of [cardiovascular events]. The authors emphasize that these agents offer a promising therapeutic option for patients with ASCVD, potentially improving cardiovascular health. This research is akin to discovering a new oasis in the vast desert of cardiovascular disease, offering a potential source of health and well-being.

Navigating the Landscape: Balancing Benefits and Risks

The study's findings also highlight the importance of [carefully weighing the benefits and risks] associated with PCSK9 inhibitors. While the agents demonstrate significant efficacy in reducing LDL-C levels and lowering cardiovascular risk, the authors acknowledge the need for ongoing research to fully understand their long-term safety profile. This approach is akin to carefully navigating the landscape of cardiovascular disease, considering the potential benefits and risks of various treatment options.

Dr. Camel's Conclusion

This study provides a comprehensive overview of the current evidence regarding PCSK9 inhibitors, highlighting their potential as a valuable therapeutic tool for managing ASCVD. The research emphasizes the need for continued research to fully understand the long-term benefits and risks of these agents, ensuring their safe and effective use in clinical practice.

Date :
  1. Date Completed 2022-07-08
  2. Date Revised 2022-07-25
Further Info :

Pubmed ID

34581425

DOI: Digital Object Identifier

PMC9273234

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.